Sugi Predict

Sugi Predict / Compounds / SCHEMBL1049822

SCHEMBL1049822

SCHEMBL1049822

CC(C)CC(=O)N1C(=O)OC[C@H]1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 3/20 0.46
▸ IL6ST P40189 1/20 0.44
▸ PPARA Q07869 1/20 0.44
▸ IDH1 O75874 8/20 0.43
▸ FAAH O00519 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ CSNK2B P67870 1/20 0.38
▸ CSNK2A1 P68400 1/20 0.38
▸ ABCB1 P08183 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029159 1.00 NAAA (0.46) NAAAIL6STPPARAIDH1FAAH
SCHEMBL1049820 1.00 NAAA (0.46) NAAAIL6STPPARAIDH1FAAH
SCHEMBL5670354 0.90 PPARA (0.46) NAAAIL6STPPARAIDH1FAAH
SCHEMBL5670355 0.90 PPARA (0.46) NAAAIL6STPPARAIDH1FAAH
SCHEMBL4205626 0.89 PPARA (0.44) NAAAIL6STPPARAIDH1FAAH
SCHEMBL17241987 0.89 IDH1 (0.45) NAAAIL6STPPARAIDH1FAAH
SCHEMBL7066044 0.89 PPARA (0.44) NAAAIL6STPPARAIDH1FAAH
SCHEMBL17241988 0.89 IDH1 (0.45) NAAAIL6STPPARAIDH1FAAH
SCHEMBL8883087 0.89 IDH1 (0.45) NAAAIL6STPPARAIDH1FAAH
SCHEMBL4205621 0.89 PPARA (0.44) NAAAIL6STPPARAIDH1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102241650-B Intermediate compound for preparing aliskiren and related preparation method ZHEJIANG JIUZHOU PHARM CO LTD 2014-05-07 — — CN claimed
WO-2024121395-A1 IAP INHIBITORS, METHODS OF MAKING THE SAME AND USES THEREOF DEBIOPHARM INTERNATIONAL SA (CH) 2024-06-13 — — WO disclosed
WO-2024121395-A1 IAP INHIBITORS, METHODS OF MAKING THE SAME AND USES THEREOF DEBIOPHARM INTERNATIONAL SA (CH) 2024-06-13 — — WO disclosed
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2023-07-18 — — US disclosed
WO-2023084124-A1 NOVEL BETA-LACTONE INHIBITORS OF HYDROLYTIC ENZYMES AND THEIR MEDICAL AND NON MEDICAL USES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-19 — — WO disclosed
EP-4180035-A1 NOVEL BETA-LACTONE INHIBITORS OF HYDROLYTIC ENZYMES AND THEIR MEDICAL AND NON MEDICAL USES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-17 — — EP disclosed
US-20210017186-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-01-21 — — US disclosed
CN-102241650-B Intermediate compound for preparing aliskiren and related preparation method ZHEJIANG JIUZHOU PHARM CO LTD 2014-05-07 — — CN disclosed
CN-102757398-A Preparation method of oxazolidinone derivatives SHANGHAI INST PHARM INDUSTRY 2012-10-31 — — CN disclosed
US-8084485-B2 6-(aminoalkyl)indazoles VITAE PHARMACEUTICALS, INC. (US) 2011-12-27 — — US disclosed
WO-2001044188-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2001-06-21 — — WO disclosed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 — — EP disclosed
US-5705658-A HYPOTENSIVE AGENTS NOVARTIS CORPORATION (US) 1998-01-06 — — US disclosed
US-5659065-A CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS NOVARTIS CORPORATION (US) 1997-08-19 — — US disclosed
US-5654445-A INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-08-05 — — US disclosed
US-5646143-A FOR TREATING A VARIETY OF CONDITIONS CIBA-GEIGY CORPORATION (US) 1997-07-08 — — US disclosed
US-5627182-A RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS CIBA GEIGY CORPORATION (US) 1997-05-06 — — US disclosed
US-5559111-A HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren CIBA-GEIGY CORPORATION (US) 1996-09-24 — — US disclosed
EP-0678500-A1 Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors CIBA-GEIGY AG (CH) 1995-10-25 — — EP disclosed
EP-0678503-A1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities CIBA-GEIGY AG (CH) 1995-10-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same HAVCR2, HPD, CYP24A1 NAAA 3012/4885IL6ST 1809/4885PPARA 1175/4885
US-20210017186-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HPD, CYP24A1 NAAA 3012/4885IL6ST 1809/4885PPARA 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.